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Tagging of RNases, such as the ribotoxin α-sarcin, with the variable domains of antibodies directed to surface
antigens that are selectively expressed on tumor cells endows cellular specificity to their cytotoxic action. A
recombinant single-chain immunotoxin based on the ribotoxin α-sarcin (IMTXA33αS), produced in the generally
regarded as safe (GRAS) yeast Pichia pastoris, has been recently described as a promising candidate for the
treatment of colorectal cancer cells expressing the glycoprotein A33 (GPA33) antigen, due to its high specific
and effective cytotoxic effect on in vitro assays against targeted cells. Here we report the in vivo antitumor
effectiveness of this immunotoxin on nude mice bearing GPA33-positive human colon cancer xenografts. Two
sets of independent assays were performed, including three experimental groups: control (PBS) and treatment
with two different doses of immunotoxin (50 or 100 μg/ injection) (n = 8). Intraperitoneal administration of
IMTXA33αS resulted in significant dose-dependent tumor growth inhibition. In addition, the remaining tumors
excised from immunotoxin-treated mice showed absence of the GPA33 antigen and a clear inhibition of angiogenesis
and proliferative capacity. No signs of immunotoxin-induced pathological changes were observed from specimens tissues.
Overall these results show efficient and selective cytotoxic action on tumor xenografts, combined with the lack of severe
side effects, suggesting that IMTXA33αS is a potential therapeutic agent against colorectal cancer.
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Colon cancer is among the most deadly ones with a sig-
nificant worldwide incidence. Its treatment by immuno-
therapy is becoming relatively successful with three
monoclonal antibodies already approved for clinical use
(Eng 2010; Tol and Punt 2010; Sliwkowski and Mellman
2013). However, its late diagnosis and metastatic progres-
sion makes the development of more efficient drugs neces-
sary. In this scenario, immunotoxins are highly specific
therapeutic agents that hold promise as antitumoral agents.
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reproduction in any medium, provided the origthe potency of a toxin, causing death of the target cells
(Pastan et al. 2007; Dougan and Dranoff 2009).
Immunotherapeutic approaches using antibodies have
been widely explored against a variety of tumors but an
effective treatment of solid tumors still remains as a prob-
lem because therapeutic antibodies must diffuse into tu-
mors through a disordered vasculature and against a
hydrostatic pressure gradient (Jain 2001; Dienstmann
et al. 2012). Immunotoxins design has greatly evolved fo-
cused on the targeting domain, mainly towards a better
penetration in solid tumors or an increase of immunotox-
ins stability or functionality (Onda et al. 2011; Gehlsen
et al. 2012). Because low–molecular weight antibody frag-
ments have been shown to have better tumor diffusion
properties, single-chain variable fragments (scFv) haveis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 In vitro cytotoxicity of IMTXA33αS, wild type
α-sarcin and scFvA33
GPA33 (+) GPA33 (−)
SW1222 LIM1215 HT29 A431
IMTXA33αS 0.03* 0.07 > > 1.00* > > 1.00*
α-Sarcin 0.8* > 1.00 > > 1.00* 1.00*
scFvA33 NM NM NM NM
*, (Carreras-Sangrà et al. 2012); NM, too high to be measurable.
IC50 (protein concentration inhibiting 50% of protein biosynthesis) (μM)
obtained for the cell lines assayed, after 72 h of incubation with the
different proteins.
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cells (Madhumati and Verma 2012; Sapra and Shor 2013).
GPA33 is an extensively studied membrane antigen
(Heath et al. 1997) overexpressed in 95% of primary or
metastatic colorectal cancers and absent in most of any
other tissue, tumoral or not. Due to its features, GPA33
represents an ideal target for immunotoxins aimed
against colon cancer cells (Scott et al. 2005; Ackerman
et al. 2008). In fact, the three mAbs approved for colon
cancer immunotherapy, bevacizumab and cetuximab or
panitumumab, are not completely specific for target colon
cancer, as they recognize the vascular endothelial growth
factor (VEGF) or the epidermal growth factor receptor
(EGFR), respectively (Sliwkowski and Mellman 2013).
Different A33 humanized monoclonal antibody (huA33)
based constructions against GPA33 antigen have been de-
scribed, including several clinical assays with radioimmuno-
conjugates using the whole antibody molecule (Welt et al.
2003; Scott et al. 2005; Almqvist et al. 2006), recombinant
scFv designs for Antibody-Directed-Enzyme-Prodrug-Ther-
apy (ADEPT) (Coelho et al. 2007; Panjideh et al. 2008) or,
more recently, preclinical assays with immuno-targeted
gold-iron oxide hybrid nanoparticles for therapeutic strat-
egies (Kirui et al. 2013).
Regarding the toxic moiety, human or fungal ribonucle-
ases (RNases) have become a new alternative for their use
in this domain as opposed to the commonly used ricin and
Diphtheria or Pseudomonas toxins (Ardelt 2013), which in
many cases show immunogenic reactivity or undesirable
side effects (Frankel et al. 2000; Schindler et al. 2001; Onda
et al. 2011). In this sense, ribotoxins are cytotoxic fungal
extracellular RNases with α-sarcin as its most outstanding
member (Lacadena et al. 2007; Olombrada et al. 2014a).
They behave as potent inhibitors of protein biosynthesis
due to its highly specific ribonucleolytic activity, which
cleaves a single phosphodiester bond of the larger molecule
of rRNA located at a universally conserved site, known as
the sarcin/ricin loop (SRL), leading to cell death by apop-
tosis (Schindler and Davies 1977; Lacadena et al. 1999;
Olmo et al. 2001; García-Ortega et al. 2010; Olombrada
et al. 2014b)
Ribotoxins have several advantages for their use as
immunotoxins toxic moiety. Namely, their small size,
high thermostability, poor immunogenicity, resistance to
proteases and highly efficient ability to inactivate ribo-
somes (Rathore and Batra 1996; Goyal and Batra 2000;
Lacadena et al. 2007; Carreras-Sangrà et al. 2008). Thus,
different ribotoxins have been used before as compo-
nents of immunotoxins, and assayed in vitro (Orlandi
et al. 1988; Wawrzynczak et al. 1991; Better et al. 1992;
Rathore et al. 1997; Goyal and Batra 2000).
Recently, we have reported the first ribotoxin-based-
scFv recombinant immunotoxin directed against human
colorectal cancer cells by the fusion of humanizedscFvA33 and α-sarcin (IMTXA33αS) (Carreras-Sangrà
et al. 2012). Incubation with nanomolar concentrations
resulted in a very high specific and effective cytotoxicity
against targeted cells in in vitro assays.
The results herein presented, in terms of its in vivo
specific antitumor effect using nude mice harbouring
colon cancer xenografts, reveal a great antitumor effect-
iveness with a strong inhibition of tumor growth, angio-
genesis and proliferative properties.
Results
IMTXA33αS inhibits protein synthesis in vitro
IMTXA33αS production and structural and in vitro
functional characterization have been previously re-
ported (Carreras-Sangrà et al. 2012). IMTXA33αS shows
a highly specific and effective cytotoxicity against colon
cancer target cells (SW1222 or LIM1215) overexpressing
the GPA33 antigen, with IC50 (protein concentration
inhibiting 50% of protein synthesis) values of 30 and 70
nM, respectively. Unlike, free wild type α-sarcin exhibits
no difference between negative and positive antigen
cells, with IC50 values of ≥1 μM (Carreras-Sangrà et al.
2012). Moreover, when we analyzed the cytotoxicity of
the scFvA33 alone against GPA33-positive SW1222 cells
cultures IC50 value was too high to be measurable
(Table 1). Thus, as expected, the scFvA33 target was not
able to induce death of the targeted cells, unless fused to
α-sarcin as part of the immunotoxin.
IMTXA33αS reduces tumor growth in vivo
To study the in vivo effect of the immunotoxin, the devel-
opment of solid tumors was induced in nude mice by in-
oculation of SW1222 cells, as GPA33-positive cell model,
in the rear right flank. SW1222-xenografts started to appear
approximately seven days after cell injection with a signifi-
cant and rapidly heterogeneous growth as previously de-
scribed (Barendswaard et al. 2001). Mice with palpable
tumors of 50–100 mm3 of volume were challenged with
immunotoxin treatment as described in Materials and
Methods. Wild type α-sarcin and scFvA33 were also
included as controls in the in vivo assay (Figure 1A).
As expected, scFvA33 administration did not affect
Figure 1 Immunotoxin inhibits colorectal tumor growth in vivo. A) Time course of the tumor volume progression of SW1222-derived
xenografts non-treated (PBS) or treated with 50 or 100 μg IMTXA33αS (IMTX50 or IMTX100, respectively), 40 μg wild type α-sarcin or 61 μg
scFvA33, per injection. α-Sarcin and scFvA33 doses were equivalent to the highest dose of immunotoxin used (IMTX100), 2.2 nanomoles in
each case. The arrow indicates the beginning of treatment Doses were given every 48 hours. *, p < 0.05; **, p < 0.01; ***, p > 0.05 vs vehicle
treated tumors. //, indicates suspension of treatment. B) Growth and C) weight measurements of excised tumors of non-treated (PBS) or
after in vivo treatment with IMTXA33αS.
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not significant from a statistical point of view. By con-
trast, treatment with wild type α-sarcin produced a
significant inhibition of tumor growth, but treatment
had to be suspended because of toxicity in mice, which
showed skin disorders, weight loss and decreased
mobility.
We then analyzed the effect of two doses of immu-
notoxin (IMTX50 and IMTX100 experimental groups)
on tumor progression compared with the vehicle
group (PBS) (Figure 1A). Treatment with the immuno-
toxin strongly slowed down tumor growth in a dose-
dependent manner. At the end of the treatment, tumor vol-
ume in animals challenged with IMTX50 and IMTX100
was reduced up to 3 to 6 times, respectively, as compared
to vehicle-treated animals (Figure 1B). Similar results were
obtained when tumor weight was considered (Figure 1C).
Tumors were analyzed by H&E staining showing the
presence of healthy tumor cells and well-vascularized
tissues with no apparent cell damage in non-treated
mice, as opposed to the cell damage and necrotic fea-
tures observed in the immunotoxin-treated tumor
cells (data not shown).IMTXA33αS reduces GPA33 antigen expression,
angiogenesis and cancer cell proliferation in vivo
The analysis of the tumors revealed that the percentage
of GPA33-positive cells in the tumors showed a large de-
crease after treatment with the immunotoxin, due to
death of target cells (Figure 2), with less than 10% of
positive area for the highest dose. Thus, most of the
remaining cells from these tumors lost the GPA33 anti-
gen and, presumably, the tumor aggressiveness.
Interestingly, when the animals were sacrificed and the
remaining tumors were excised significant differences in
their morphologic features were evident. Tumors from
the non-treated group were solid and well vascularized.
On the other hand some of the IMTX100-treated
mice tumors were more whitish, squishy and cyst-like
(Figure 3A). This colour differences were suggestive of
effects on the angiogenic process. In fact, tumor
vascularization was impaired by the immunotoxin, as
the number of blood vessels was smaller, as deter-
mined by CD31 staining (Figure 3B), confirming what
was observed in the macroscopic analysis.
The proliferative potential of cancer cells present in
the tumors was also analyzed. A significant reduction of
Figure 2 IMTXA33αS-treated tumors show lack of GPA33 antigen in vivo. A) GPA33-positive cells (green). Scale bars: 50 μm. B) Quantification of
GPA33-positive cells. Statistical analysis of IMTX50 or IMTX100-treated tumors vs vehicle-treated tumors rendered p <0.001.
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tumors, as indicated by the dose dependent decrease in the
number of Ki67-positive cells (Figure 4A and C). Moreover,
immunotoxin administration increased the number of ac-
tive caspase 3-positive cells, indicating tumor cells death by
apoptosis (Figure 4B and C).
IMTXA33αS does not produce adverse side effects
Growth of the mice was not affected by treatment with
IMTXA33αS in any of the doses assayed, considering
their weight (Figure 5A) and external appearance. In this
sense, regardless of the group to which they belonged,
weight was increased in about 20% at the end of the
treatment.
None of the mice showed histomorphologic changes
in a macroscopic analysis resulting from immunotoxin
treatment. Moreover no significant changes were ob-
served in the histological analysis by H&E staining in
any of the organs analyzed, regardless of the experimen-
tal group they belonged (Figure 5B).
Discussion
ScFv-immunotoxins have been lately used for experimental
therapeutic approaches due to its more favourable penetra-
tion and diffusion features in solid tumor tissues. Withinthis idea, we have recently reported the high specificity and
effectiveness on in vitro assays of two recombinant
scFv-immunoconjugates, based on the fungal RNases
α-sarcin and RNase T1, against colon cancer targeted
cells (Carreras-Sangrà et al. 2012; Tomé-Amat et al. 2012).
In this work we move one step further and demon-
strate the potential of IMTXA33αS for in vivo applica-
tions, using SW1222-induced xenografts, as a model of
GPA33-positive colon cancer. The results have shown a
clear inhibition effect on tumor growth accompanied by
a significant decrease in the proliferative and angiogenic
capacities of the treated tumors, as determined by Ki67
and CD31 labeling. The inhibition of protein biosynthesis
in immunotoxin-treated tumors, due to α-sarcin specific
RNase activity, led to apoptosis causing cell death, as deter-
mined by active-caspase 3 labeling. This mechanism is a
well-known feature of the ribotoxic action of this toxin
(Olmo et al. 2001; Lacadena et al. 2007).
Furthermore, treatment with the highest dose of
immunotoxin resulted in a residual tumor mass, lack-
ing the GPA33 antigen and with a cyst-like appearance.
GPA33 belongs to the immunoglobulin superfamily
with homology to tight junction-associated proteins.
It’s closest homologous include the junction adhesion
molecules (JAM) or the CEA-related cell adhesion
Figure 3 IMTXA33αS impaired angiogenesis on in vivo treated tumors. A) Representative images of the excised remaining tumors of
non-treated (PBS) or treated (IMTX50, IMTX100) experimental groups. Scale is in centimeters. Each column shows three examples from each
group. B) CD31-positive cells (red). Scale bars: 60 μm. Quantification of the number of blood vessels is shown in the corresponding graph.
Statistical analysis of IMTX50 or IMTX100-treated tumors vs vehicle-treated tumors rendered p <0001.
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which are involved in tumor proliferation (Goetsch
et al. 2013) or tumor angiogenesis (Kuespert et al.
2006), respectively. Thus, the absence of the GPA33
antigen after treatment with IMTXA33αS would be
consistent with the observed anti-angiogenic effect and
the decrease in the proliferative potential of the residual
tumor mass. These results would suggest a correlation be-
tween GPA33-expression level and aggressiveness or the
tumor, as previously described for JAM in relation to poor
prognosis of breast cancer (McSherry et al. 2009).
Moreover, along with the high antitumor effectiveness
of IMTXA33αS, adverse side effects were not observed
at the histological level or in the development of the
treated mice. Thus the scFvA33 target domain directs α-
sarcin to the target cells avoiding the nonspecific toxicity
shown in the in vivo assay with free wild type α-sarcin
(Figure 1). Similar effects have been previously described
for free wild type α-sarcin and other ribotoxins, like
mitogillin, in clinical trials (Goldin et al. 1966; Rogaet al. 1971). For example, neurologic symptoms, gastro-
intestinal toxicity or frequent skin rash have been previ-
ously described for free α-sarcin in vivo assays with mice
(Goldin et al. 1966). Mitogillin has also been evaluated
by repeated-dose toxicity tests performed in mice, dogs
and monkeys (Roga et al. 1971). In the particular case of
mice that received 0.2 mg/kg/day, only two of ten mice
survived the test period, and all of them showed weight
loss and organs injury (Roga et al. 1971). Similar effects
were described in the other trials (Roga et al. 1971). This
explains why in the 1970s these proteins were aban-
doned as promising antitumoral agents. However, none
of these effects have appeared in the immunotoxin-
treated mice, despite having used fivefold higher doses
of immunotoxin (in nmoles) than those described for
the ribotoxin. A result which again favours the interpret-
ation, that the immunotoxin action is highly specific
in vivo. Thus, IMTXA33αS shows both high efficacy and
specificity against colon cancer tumors on in vivo assays
with undetectable unwanted side-effects. Further steps
Figure 4 IMTXA33αS-treated tumors show inhibition of cancer cell proliferation and induction of cancer cell apoptosis in vivo. A)
Ki67-positive cells (green) and B) active caspase-3-positive cells (green) in tumors. Scale bars: A, 60 μm; B, 60, 30, 40 μm (from left to right).
C) Quantification of Ki67-positive cells (A) and active-caspase-3-positive cells (B) in the tumors are shown in the corresponding graphs.
Statistical analysis of IMTX50 or IMTX100-treated tumors vs vehicle-treated tumors rendered p < 0.001 (A) and p < 0.05 (B).
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via of administration, determination of the maximum
tolerated dose of the molecule, limiting toxicities or a
more thorough analysis of the effect on the different tis-
sues and organs, among others. However, the results
herein presented would be enough and consistent to be
considered as a proof of concept.
As mentioned before, other immunoconjugates con-
structs have been previously used in preclinical or clin-
ical trials based on mAbA33, most of them using the
whole antibody molecule conjugated with radionuclides
(Scott et al. 2005; Almqvist et al. 2006; Panjideh et al.
2008). In these clinical trials no toxicity in normal colon
was observed, although GPA33 could be detected in the
colonic epithelium (Scott et al. 2005; Almqvist et al.
2006; Ackerman et al. 2008; Panjideh et al. 2008). The
surface persistence of the GPA33 antigen and normal in-
testinal epithelium shedding contribute to the very good
retention in tumor tissue and the rapidly released form
normal cells (Almqvist et al. 2006; Ackerman et al.2008), supporting the selective localization into the
tumor of mAbA33 immunoconjugates, as shown by
in vivo biodistribution in mice models (Scott et al. 2005;
Almqvist et al. 2006; Panjideh et al. 2008). Our results
provide further evidence of the potential of GPA33 anti-
gen as a specific tumor-marker for colon cancer becom-
ing a good alternative to those actually used in therapy
(Sliwkowski and Mellman 2013). In this sense, biodistri-
bution studies with IMTXA33αS would provide useful
information about half-life and localization of the immu-
notoxin and would be a step further in the thorough
characterization of its antitumor action.
On the other hand, RNases from different origins have
arisen as new candidates for the toxic domain of immu-
notoxins versus the commonly used ricin, Diphtheria or
Pseudomonas toxins, to improve their efficacy or to cir-
cumvent immunogenicity or side adverse effects (Ardelt
2013; D’Avino et al. 2014). In regard to IMTXA33αS im-
munogenicity, neither ribotoxins as α-sarcin (Rathore
and Batra 1996; Goyal and Batra 2000; Lacadena et al.
Figure 5 IMTXA33αS-treated mice show no major toxicity effects in vivo. A) Mice weight measurement before and after treatment. Black
bars (before treatment), white bars (after treatment). Increase in weight (g) is indicated for each experimental group. No significant statistical
differences were observed between the different experimental groups. B) Hematoxylin & eosin staining of representative tissue sections from
non-treated (PBS) or treated- (IMTX50 or IMTX100) mice. Scale bars: 120 μm (liver), 40 μm (kidney) and 100 μm (brain). No significant differences
in histological tissue analysis of the selected organs were observed.
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et al. 2003; Scott et al. 2005) would contribute to a po-
tential immune response against the immunotoxin (Car-
reras-Sangrà et al. 2012), avoiding the inactivation of its
antitumor action. This issue should be considered and
confirmed when assayed in future clinical trials. In fact,
in addition to the ribotoxins advantages mentioned
above for their use as immunotoxins toxic moiety, theresults show that nonspecific toxicity associated with
ribotoxins is extremely reduced when included in an
immunotoxin.
As mentioned in the Introduction, different ribotoxins
have been used before as components of immunotoxins
and assayed in vitro (Orlandi et al. 1988; Wawrzynczak
et al. 1991; Better et al. 1992; Rathore et al. 1997; Goyal
and Batra 2000). Unfortunately none of the ribotoxin-
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characterization, most probably due to their larger size,
which could hinder their correct internalization into
solid tumors, or to the low structural stability of the
immunoconjugates prepared. IMTXA33αS is the first
immunotoxin based on ribotoxins and the scFvA33 that
has demonstrated its antitumor effectiveness on in vivo
assays.
Conclusion
IMTXA33αS, an immunotoxin based in ribotoxin α-
sarcin, exhibits highly specific antitumor effectiveness in
mice harbouring human colon tumor xenografts. It also
exhibits anti-angiogenesis, anti-proliferative properties,
and lacks adverse side effects. Thus, the results herein
presented are a step further in the potential clinical ap-




All chemicals were of molecular biology grade and used
without further purification.
Protein production, purification and in vitro
characterization
IMTXA33αS was expressed in Pichia pastoris. Structural
and in vitro-functional characterization of the isolated
immunotoxin was performed as previously reported
(Carreras-Sangrà et al. 2012; Tomé-Amat et al. 2012) be-
fore assayed in vivo. If needed, the purified immunotoxin
was lyophilized and stored at −80°C until use.
Cell line culture
Human colon carcinoma SW1222 and LIM1215 cells
were provided by Dr. Carl Batt under the partnership
Cornell University-Ludwig Institute of Cancer Research.
SW122 cells were used as GPA33-positive cells for xeno-
grafts induction. Both cell lines were authenticated in
2010 by short tandem repeat (STR) analysis. Cells were
also tested by flow cytometry, using a double labelling of
GPA33 and CD44, characteristic of this cell line, imme-
diately before any in vitro or in vivo assays. Double
checking of GPA33 expression was also made by western
blot using cellular extracts. Human colon adenocarcin-
oma HT-29 (ATCC:HTB-38) and epidermoid carcinoma
A431 (ATCC:CRL-1555) cells were obtained from the
ATCC Cell Biology Collection which carried out its
characterization by STR analysis. Cells were grown as
described (Carreras-Sangrà et al. 2012; Tomé-Amat
et al. 2012) in Dulbecco’s modified Eagle’s medium
(DMEM), containing glutamine (300 μg/ml), 50 U/ml of
penicillin, and 50 μg/ml of streptomycin, and supple-
mented with 10% fetal bovine serum (FBS). Incubationwas performed at 37°C in 5% CO2 humidified atmos-
phere. Harvesting and propagation of cultures were rou-
tinely performed by trypsinization. The number of cells
used was determined using a haemocytometer.
In vitro cytotoxicity assay
To evaluate the in vitro cytotoxic activity of α-sarcin-
based constructions, inhibition of protein biosynthesis
was determined as described (Lacadena et al. 2007;
Carreras-Sangrà et al. 2012). GPA33-positive cells
(SW1222 and LIM1215) and GPA33-negative cells
(HT-29 and A431) were incubated with different con-
centrations of IMTXA33αS, free fungal wild-type
α-sarcin or scFvA33. After 72 h of incubation at 37°C,
the medium was removed and replaced with a fresh
one supplemented with 1 mCi per well of L-[4,5-3H]-
Leucine (166 Ci/mmol; Amersham, UK). After an
additional incubation for 6 h, the medium was
also removed and cells were fixed with 5.0% (w/v)
trichloroacetic acid in PBS and washed three times
with cold ethanol. The resulted dried pellet was dis-
solved in 0.2 ml of 0.1 M NaOH containing 0.1% SDS,
and radioactivity was counted on a Beckman LS3801
liquid scintillation counter. To calculate the IC50
values (protein concentration inhibiting 50% protein
synthesis) the results were expressed as a percentage
of the radioactivity incorporated in control samples in-
cubated without any of the three proteins, wild type α-
sarcin, scFvA33 or the immunotoxin IMTXA33αS.
Three independent replicate assays were conducted to
calculate the average IC50 values.
Animal treatment
All animal procedures were performed with the ap-
proval of the Complutense University Animal Experi-
mentation Committee, according to the European
official regulations.
Balb/c nude male mice (7 weeks old) were purchased
from Harlan Laboratories S.A. (Barcelona, Spain) to
evaluate the in vivo effect of IMTXA33αS against colo-
rectal cancer induced xenografts. Two sets of assays
were performed, using the Animal Facilities of either the
Complutense University or the Centro Investigaciones
Biológicas-Consejo Superior Investigaciones Biológicas
(CIB-CSIC) in Madrid.
Mice were allocated into three experimental groups
(n = 8): PBS (phosphate buffered saline), IMTX50 and
IMTX100 (treatment with 50 or 100 μg of immuno-
toxin per injection, respectively). Prior to the experi-
ments, animals were given a 7-day adaptation period
with free access to food and water at all times. Each
mouse received a subcutaneous injection into the right
flank of 2×106 SW1222 cells, resuspended in 100 μl
PBS and 100 μl of Matrigel (BD Biosciences). Once the
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intraperitonealy either with PBS or immunotoxin. Seven
doses, every 48 hours, of PBS or the two different amounts
of immunotoxin (50 or 100 μg) were given. Two control
groups, free-α-sarcin wild type (n = 3) and scFvA33 (n = 3)
were also included. In this case, we used doses of 40 and
61 μg per injection, respectively, which were equivalent to
the highest dose of immunotoxin used (IMTX100), (2.2
nanomoles),
Tumors were routinely measured during this period with
an external caliper, and volume was calculated as (width/2)2
x (length/2). Mice were also weighted throughout the ex-
periment. At the end of the treatment, animals were sacri-
ficed and tumors and organs were collected. Tumors were
divided in portions and stored fixed in buffered 4% parafor-
maldehyde (PFA) or in Tissue-Tek (Sakura Finetek Europe)
for immunofluorescence staining.ImmunofluorescenceTumor analysis
Histological analyses of excised tumors were performed.
Tissue-teK embedded tumor sections of 8–10 μM
thickness were obtained using a cryotome (Criocut
Leica CM), fixed in methanol, washed with IFF buffer
(5% FBS, 1% BSA, PBS) and incubated with anti-GPA33
polyclonal human mAb A33 (Santa Cruz Biotechnologies),
anti-CD31 (Pharmingen/BD Biosciences), anti-Ki67 (Thermo
Scientifics) or anti-Caspase3 (Cell Signaling Technology)
antibodies. CD31, Ki67 and active-caspase3 are well-
stablished markers for angiogenesis, proliferation and
apoptosis, respectively. Secondary anti-rabbit anti-
bodies, labelled with AlexaFluor 647 for GPA33 and
Ki67 detection or anti-mouse AlexaFluor 488 for
CD31 and Caspase3, were purchased from Invitrogen.
Cell nuclei were stained with Prolong Gold with 40,6-
diamidino-2-phenylindole (DAPI) (Molecular Probes).
All these incubations were performed at room temperature.
A Leica TCS P2 confocal microscope and the correspond-
ing LCS lite software were used to obtain the fluorescence
images. At least three sections of two representative tumors
from each experimental group were used.Histopathological analysis
Brain, spleen, liver, kidneys, lungs and intestine were
collected at the end of the treatment and fixed in 4%
PFA. Collected organs were visually analysed for pos-
sible macroscopic changes resulting from treatment.
Histological assessment of organs samples was per-
formed by hematoxylin and eosin (H&E) staining. The
samples were sliced into sections as described above,
fixed in PFA and stained for H&E analysis. Morpho-
logical changes were evaluated using a light micro-
scope and H&E-stained images were acquired.Statistical analysis
ANOVA with a post hoc analysis by the Student-
Newman-Keuls’ test was used to compare variations in
the mean tumor sizes at different treatment time points
in each experimental group. Differences between ex-
perimental groups were considered statistically signifi-
cant at P < 0.05. All values were expressed as arithmetic
means ± sem (standard error of the media). For im-
munofluorescence tumor statistical analysis, at least
three sections of two representative tumors from each
experimental group were used.
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